Hi-Tech Deal Broadens Akorn Consumer Business
This article was originally published in The Tan Sheet
Executive Summary
Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.
You may also be interested in...
Bausch + Lomb Buy Vaults Valeant Into Consumer Eye Care Space
Bausch + Lomb retains its name and becomes a division of Valeant in the $8.7 billion acquisition expected to close in the 2013 third quarter.
Novartis Wraps Up Alcon Ownership, Forms New Eye Care Unit
Novartis will create an eye care division, its second-largest unit and the fifth growth platform in its health care portfolio, with full ownership of Alcon, the world's largest eye care company.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.